NOV 09, 2020 9:13 AM PST

COVID-19 Vaccine by Pfizer More than 90% Effective

WRITTEN BY: Annie Lennon

A preliminary analysis of Pfizer and BioNTech's COVID-19 vaccine shows that it can prevent over 90% of people from contracting COVID-19. 

For the study, researchers tested the vaccine on over 43,000 people across six countries: the US, Germany, Brazil, Argentina, South Africa, and Turkey. During the Phase 3 trial, volunteers either received the COVID-19 vaccine, administered in two shots around three weeks apart, or a placebo alternative such as a meningitis vaccine. Neither doctors nor patients knew which they had. 

So far, the results look positive. From an interim analysis of the first confirmed 94 cases of COVID-19 among those involved in the research, scientists found that fewer than 10% of infections- or around eight people- had received the vaccine. This means that over 90% of the cases were people who had received the placebo. 

Pfizer has said that the vaccine had an efficacy rate of more than 90% at seven days after the second dose, meaning that protection is achieved within 28 days of beginning the vaccination process. While the companies behind the vaccine aim to have it approved by the end of the month, they aim to be able to assess 164 confirmed cases of COVID-19 infection among trial participants before final results are published.

The vaccine itself is based on a new approach involving messenger RNA (mRNA). Unlike other vaccines that directly use the virus, this vaccine uses the virus's mRNA to cause cells in the body to produce proteins that resemble the virus. This then triggers an immune response that recognizes and attacks these proteins, which are theoretically summoned again if the virus enters the body. 

While the vaccine is deemed to be effective, the CEO of Pfizer, Dr Albert Bourla, said that it is still unknown how long protection from the vaccine will last. He added that it is likely that people will need periodical vaccinations to ensure immunity. Regardless, Bourla has said that Pfizer expects to produce 50 million vaccine doses by the end of this year and 1.3 billion next year. 

 

Sources: BBCCNNThe Guardian

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
APR 16, 2022
Neuroscience
A New Approach to Seizure Treatment
APR 16, 2022
A New Approach to Seizure Treatment
There are many types of epilepsy, a brain disorder that causes recurrent seizures or periods of altered behaviors or sen ...
MAY 09, 2022
Health & Medicine
How Adult Acne Affects Women
MAY 09, 2022
How Adult Acne Affects Women
Although commonly thought of as a disease of adolescence, acne is said to affect nearly 50% of women in their 20s and ne ...
MAY 12, 2022
Drug Discovery & Development
Gut Bacteria Composition Predicts Resposnse to Statins
MAY 12, 2022
Gut Bacteria Composition Predicts Resposnse to Statins
The composition of the gut microbiome is predictive of patient responses to statins. The corresponding study was publish ...
MAY 23, 2022
Drug Discovery & Development
A Possible Therapy for Infantile Spasms
MAY 23, 2022
A Possible Therapy for Infantile Spasms
Researchers at Texas Children’s Hospital have identified a possible cause of infantile spasms (IS) as well as a po ...
MAY 31, 2022
Drug Discovery & Development
Computer Models Help Find Antibiotics to Fight Drug-Resistant Pathogens
MAY 31, 2022
Computer Models Help Find Antibiotics to Fight Drug-Resistant Pathogens
Antibiotics were a revolutionary tool in the fight against bacterial infections. In recent years, however, the emergence ...
JUN 09, 2022
Cancer
A Case Study May Identify a Novel Gene Therapy for Pancreatic Cancer
JUN 09, 2022
A Case Study May Identify a Novel Gene Therapy for Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive pancreatic cancer with limited treatment options.  PDA ...
Loading Comments...